Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with cyclophosphamide, etoposide, prednisolone, and vincristine for reimbursement as a treatment option for the treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy.
This is written in the approval document as:
Treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HSE (1) | CD20 + | Non-Hodgkin Lymphoma | Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine |